| Adjunctive interventions in myocardial infarction: the role of statin therapy. | |
| | |
MedLine Citation:
|
PMID: 18417069 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Statin therapy has reduced cardiovascular morbidity and mortality across the spectrum of atherosclerosis. The administration of statins has been demonstrated to be effective in primary and secondary prevention clinical trials evaluating patients with high and low risk-factor profiles. The presumed mechanism of benefit of hypolipidemic therapy in the prevention of atherosclerotic disease was a reduction in the deposition of atherogenic lipoproteins in vulnerable areas of the coronary vasculature. Subsequent experimental studies with statins demonstrated a variety of potentially beneficial effects that would extend clinical benefit beyond lipid-lowering per se. Statin therapy beneficially alters inflammation, coagulation and fibrinolytic parameters, endothelial function, vasoreactivity, and platelet function. The demonstration of the non-lipid or pleiotropic effects provided the theoretical basis for a possible role as an adjunctive therapy in acute coronary syndromes. Retrospective analysis of a variety of early trials indicated a potential benefit of statins during acute ischemic syndromes. Recent clinical trials have addressed this important clinical question in a prospective controlled manner. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) and the Thrombolysis In Myocardial Infarction (TIMI)-22 studies present strong clinical evidence in favor of the administration of statins as adjunctive therapy in acute ischemic syndromes. |
| | |
Authors:
|
Peter H Jones; John A Farmer |
Related Documents
:
|
7137149 - Contrasting patterns of familiality for cholesterol and triglyceride in finland accordi... 2248619 - Influence of serum triglycerides on the hdl pattern in normal subjects and patients wit... 20027659 - Statin therapy decreases myocardial function as evaluated via strain imaging. 8280789 - Increased oxidizability of plasma low density lipoprotein from patients with coronary a... 17721009 - Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: suba... 3773179 - High-density lipoprotein cholesterol measurements. a help or hindrance in practical cli... 7879929 - Low-frequency spectral power of heart rate variability is not a specific marker of card... 1744959 - 25-year mortality after surgical repair of congenital heart defect in childhood. a popu... 9112879 - Viability after myocardial infarction: can it be assessed within five minutes by low-do... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current atherosclerosis reports Volume: 10 ISSN: 1534-6242 ISO Abbreviation: Curr Atheroscler Rep Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-04-17 Completed Date: 2008-05-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897685 Medline TA: Curr Atheroscler Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 142-8 Citation Subset: IM |
Affiliation:
|
Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Room 525D, Houston, TX 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
drug therapy Anticholesteremic Agents / pharmacology, therapeutic use Coronary Artery Disease / pathology, prevention & control* Coronary Circulation / drug effects Coronary Occlusion / pathology Dyslipidemias / drug therapy Endothelium, Vascular / drug effects, physiopathology Heptanoic Acids / pharmacology, therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology, therapeutic use* Myocardial Infarction / drug therapy, physiopathology, prevention & control* Plasminogen Activator Inhibitor 1 / blood Pravastatin / pharmacology, therapeutic use Pyrroles / pharmacology, therapeutic use Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Plasminogen Activator Inhibitor 1; 0/Pyrroles; 110862-48-1/atorvastatin; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PPARgamma agonists and coronary atherosclerosis.
Next Document: Aspirin resistance in atherosclerosis.